Media Articles Related to Kineret (Anakinra)
Rheumatoid Arthritis (RA)
Source: MedicineNet Amyloidosis Specialty [2015.03.17]
Title: Rheumatoid Arthritis (RA)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 3/17/2015 12:00:00 AM
Rheumatoid arthritis costs the economy Â£4.75bn but care still "disgracefully low"
Source: Arthritis / Rheumatology News From Medical News Today [2015.03.09]
The treatment of rheumatoid arthritis, which costs the NHS Â£560m annually is not given a high enough priority, partly because government and health service reforms to improve patient outcomes are...
Baricitinib superior to placebo in reducing rheumatoid arthritis disease activity in second Phase 3 study
Source: Arthritis / Rheumatology News From Medical News Today [2015.02.24]
Eli Lilly and Company and Incyte Corporation have announced that the investigational medicine baricitinib demonstrated a statistically significant improvement compared to placebo in a second...
Patient Story: Rheumatoid Arthritis and Pregnancy
Source: MedicineNet Birth Defects Specialty [2014.12.09]
Title: Patient Story: Rheumatoid Arthritis and Pregnancy
Category: Doctor's Views
Created: 1/26/2012 12:00:00 AM
Last Editorial Review: 12/9/2014 12:00:00 AM
Rheumatoid Arthritis - When Do I Call the Doctor?
Source: MedicineNet Carpal Tunnel Syndrome Specialty [2014.12.01]
Title: Rheumatoid Arthritis - When Do I Call the Doctor?
Category: Doctor's Views
Created: 7/7/2001 12:00:00 AM
Last Editorial Review: 12/1/2014 12:00:00 AM
Published Studies Related to Kineret (Anakinra)
Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in
patients with heart failure and preserved ejection fraction (from the D-HART
pilot study). 
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome of
exercise intolerance due to impaired myocardial relaxation and/or increased
stiffness. Patients with HFpEF often show signs of chronic systemic inflammation,
and experimental studies have shown that interleukin-1 (IL-1), a key
proinflammatory cytokine, impairs myocardial relaxation...
Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. [2011.07]
CONTEXT: Obesity induces low-grade inflammation that may promote the development of insulin resistance. IL-1 is one of the key inflammatory factors. OBJECTIVE: The objective of the study was to demonstrate improvement of insulin sensitivity by blocking IL-1... CONCLUSIONS: Our results suggest that anakinra does not improve insulin sensitivity in obese, insulin-resistant, nondiabetic subjects.
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). [2011.05]
OBJECTIVES: To assess the efficacy of the interleukin 1 receptor antagonist anakinra in systemic-onset juvenile idiopathic arthritis (SJIA)... CONCLUSIONS: Anakinra treatment is effective in SJIA, at least in the short term. It is associated with normalisation of blood gene expression profiles in clinical responders and induces a de novo IFN signature. Trial Registration Number: NCT00339157.
Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). [2010.05.15]
Acute myocardial infarction (AMI) initiates an intense inflammatory response in which interleukin-1 (IL-1) plays a central role...
Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. [2009.03.15]
OBJECTIVE: To evaluate the clinical response, safety, and tolerability of a single intraarticular injection of anakinra in patients with symptomatic osteoarthritis (OA) of the knee... CONCLUSION: Anakinra was well tolerated as a single 50-mg or 150-mg intraarticular injection in patients with OA of the knee. However, anakinra was not associated with improvements in OA symptoms compared with placebo.
Clinical Trials Related to Kineret (Anakinra)
The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria [Completed]
An open labelled trial of Kineret (anakinra) induction therapy (100mg./day) in over a four
week period in the treatment of Familial Cold Urticaria.
Familial Cold Urticaria (FCU) is a rare autosomal dominant condition manifesting symptoms
triggered by exposure to cold and variable in expression. Currently there is no standard
reliable agent available for the treatment of patients with FCU. This study will evaluate the
efficacy of Kineret (anakinra), an interleukin 1 receptor antagonist in induction and
maintenance therapy in patients with FCU.
Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA) [Completed]
The purpose of this study is to evaluate the percentage of subjects in Australian clinical
practice continuing treatment with Anakinra (Kineret®) at the end of study week 48 in
subjects with active RA. The continued use of Kineret® will be based on pre-defined response
assessment criteria for subjects with active RA.
Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire [Completed]
The primary purpose of this study is to assess the ease-of-use of SimpleJectTM compared to
pre-filled syringe(s) when using Kineret® in RA subjects. The secondary purpose of this study
is to assess the level of fear and anxiety associated with the use of both injection methods,
to assess safety when using SimpleJectTM and to evaluate the Ease-of-Administration
Questionnaire (EAQ) in terms of the quality of items, item performance, and the instrument
A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis [Recruiting]
- Severe atopic dermatitis, also known as eczema, is a chronic inflammatory skin
condition that affects both children and adults and causes severe itching and skin
redness. Current treatments of atopic dermatitis include topical creams and lotions,
light therapy, and medications. However, the difficulty with long-term treatment for
the chronic and severe nature of the disease requires more effective and
better-tolerated therapeutic options.
- Anakinra is a drug that blocks a substance called interleukin-1 (IL-1), which may be
important in causing the inflammation in atopic dermatitis. Researchers are interested
in determining whether anakinra can be used to help treat atopic dermatitis. Anakinra
has been approved by the Food and Drug Administration to treat rheumatoid arthritis in
adults and children, but it has not been approved for use in adults or children with
atopic dermatitis and is considered an experimental treatment in this study. In this
study Anakinra will be administered as an injection under the skin every day for 3
- To assess the safety and effectiveness of using anakinra to treat severe atopic dermatitis
- Children between 10 and 18 years of age who have been diagnosed with severe atopic
dermatitis that has not responded to standard treatment.
- Initial Screening: Participants will have an initial screening visit with a complete
physical examination and medical history, blood and urine tests, photographs of the
skin ,skin biopsy, and other tests as required.
- Run-in Period: At the screening visit, participants will receive a diary card and will
be asked to track their atopic dermatitis symptoms on standard treatment for 2 months.
- Start of Treatment: At the end of the 2 month Run-in period participants will return
for an inpatient visit (2 days) to receive the initial dose of anakinra and will be
watched for any side effects. During the inpatient visit, participants will have
additional examinations and blood and urine tests, and will be instructed on how to
administer the anakinra injections at home.
Treatment Period: - Participants will return once a week for the first 2 weeks of treatment,
at the end of the first month, and then once a month for the following 2 months, for a
physical exam and blood tests. Participants will be asked to record symptoms related to
their atopic dermatitis, anakinra administration and any side effects related to the
anakinra on the diary card. The diary cards will be reviewed and collected at each visit.-
End of Treatment Period: At the end of 3 months of treatment with anakinra, participants
will again be asked to record symptoms related to their atopic dermatitis on the diary card.
Participants will be seen once a month for 3 months for a physical exam, blood tests and
review of the diary card. . The final study visit will take place at the end of the 3rd
month and will include a physical exam, blood tests, photographs and skin biopsy.
Anakinra in Hidradenitis Suppurativa [Recruiting]
Aim of this double-blind, randomized, controlled clinical trial is to compare the safety and
the efficacy of anakinra over placebo for the management of patients with hidradenitis
suppurativa (HS) of Hurley II and Hurley III disease stage. Patients will be evaluated on
subsequent follow-up visits. Two scores will be applied: disease activity as assessed in the
protocol by the investigator; and Sartorius score. Primary efficacy endpoint will be the
comparisons of visual analogue scores, of disease activity, of Sartorius score and of
dermatology life quality index between the two groups of treatment over follow-up.
Reports of Suspected Kineret (Anakinra) Side Effects
Alanine Aminotransferase Increased (6),
Cytolytic Hepatitis (4),
Aspartate Aminotransferase Increased (4),
Liver Injury (3),
Drug Ineffective (3), more >>